Literature DB >> 1407890

Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy.

N Kadar1, J H Malfetano, H D Homesley.   

Abstract

OBJECTIVE: To determine the factors that influence the survival of patients with endometrial carcinoma histologically confined to the uterus.
METHODS: Retrospective analysis was conducted of 262 surgically staged cases using multiple regression (Cox proportional hazards model).
RESULTS: After excluding patients with clear-cell and serous tumors, which were adverse prognostic factors unrelated to any other variables, we found that survival was adversely affected by increasing stage, tumor grade and depth of myometrial invasion, cervical stromal and vascular space invasion by tumor, and increasing age. Tumor grade, myometrial invasion, and cervical involvement by tumor exerted their effects on survival as dichotomous rather than as ordinal variables. The greatest effect on survival was obtained by dichotomizing grade as grade 3 versus grade 1 or 2, myometrial invasion as invasion of more versus less than the inner third of the myometrium, and cervical spread as the presence versus absence of stromal invasion. The joint effect of the tumor-related prognostic factors was best expressed by constructing three risk groups consisting of patients with zero or one, two, and three or four risk factors. These risk groups were associated with 5-year survival rates of 97, 66, and 17%, respectively. After adjustment for risk factors, pelvic radiation did not affect survival significantly, although there was a trend toward improved survival of subjects with two risk factors who received pelvic radiation (70 versus 50% survival at 5 years).
CONCLUSIONS: The number of tumor-related risk factors present is the best predictor of survival of patients with endometrial carcinoma confined to the uterus, and may provide the optimal basis for individualization of treatment.

Entities:  

Mesh:

Year:  1992        PMID: 1407890

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Radiotherapy: Intermediate-risk endometrial cancer--adjuvant treatment.

Authors:  Patricia J Eifel
Journal:  Nat Rev Clin Oncol       Date:  2010-10       Impact factor: 66.675

2.  Racial differences in surgically staged patients with endometrial cancer.

Authors:  M L Hicks; W Kim; J Abrams; C C Johnson; A C Blount; G P Parham
Journal:  J Natl Med Assoc       Date:  1997-02       Impact factor: 1.798

3.  Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome.

Authors:  A M Gassel; J Backe; S Krebs; S Schön; H Caffier; H K Müller-Hermelink
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

4.  Body mass index, dose to organs at risk during vaginal brachytherapy, and the role of three-dimensional CT-based treatment planning.

Authors:  John M Boyle; Oana Craciunescu; Beverley Steffey; Jing Cai; Junzo Chino
Journal:  Brachytherapy       Date:  2014-01-16       Impact factor: 2.362

5.  Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion.

Authors:  Taek Sang Lee; Jae Weon Kim; Dae Yeon Kim; Young Tae Kim; Ki Heon Lee; Byoung Gie Kim; D Scott McMeekin
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

6.  Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer.

Authors:  Soledad Jorge; June Y Hou; Ana I Tergas; William M Burke; Yongmei Huang; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2016-01-06       Impact factor: 5.482

7.  Small bowel intussusception in metastatic endometrial carcinoma.

Authors:  G R Kirk; D O'Rourke; R Ashe; W D Clements
Journal:  Ulster Med J       Date:  1999-11

Review 8.  Adjuvant therapy for endometrial cancer.

Authors:  Maria C Deleon; Natraj R Ammakkanavar; Daniela Matei
Journal:  J Gynecol Oncol       Date:  2014-04-09       Impact factor: 4.401

9.  Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma.

Authors:  Agnes Y Bahng; Christina Chu; Paul Wileyto; Stephen Rubin; Lilie L Lin
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

10.  Contemporary clinical management of endometrial cancer.

Authors:  Helen E Dinkelspiel; Jason D Wright; Sharyn N Lewin; Thomas J Herzog
Journal:  Obstet Gynecol Int       Date:  2013-06-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.